By Heather Han, MD and Sue Friedman
Metastatic Hereditary Breast Cancer Research
There are major gaps in research, resources, and support for people with metastatic breast cancer – cancer that has spread beyond the breast and lymph nodes. A promising area of research is focusing on new treatments for hereditary metastatic breast cancer caused by a mutation in BRCA1, BRCA2, and other inherited mutations.
Cancers in people with BRCA mutations lack the ability to repair certain types of damage to their DNA. Therefore, these tumors are very sensitive to treatment with a type of chemotherapy known as platinum-based chemotherapy and new drugs known as PARP inhibitors. Veliparib is one of the PARP inhibitors that is being studied in clinical trials. Veliparib has been studied as a single-agent and also in combination with chemotherapy.
BROCADE 3 Study
BROCADE 3 is phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with/without Veliparib in HER2 negative BRCA-associated locally advanced or metastatic breast cancer. BROCADE3 is studying whether adding Veliparib to chemotherapy (carboplatin and paclitaxel) versus placebo with chemotherapy improves outcomes. The study is currently enrolling patients in the United States as well as internationally. Both women and men with BRCA mutations are eligible to participate in this study if they have received no more than two prior chemotherapy courses for their locally advanced or metastatic HER2 negative breast cancer.
If you are interested in learning more about BROCADE 3, you can click here to find a study site near you.
Participating in Hereditary Cancer Research
FORCE’s Featured Research page and Clinical Research Matching Tool help people find cancer prevention, detection, and treatment studies. Further, you can ask your health care providers if you qualify for other research studies.
Additionally, FORCE is conducting an important survey for anyone with, or at high risk for hereditary cancer. The survey will improve our understanding of the factors that help and hinder participation in clinical research. The survey is open both to people who have, as well as those who have not participated in research.
Through hereditary cancer research scientists can develop better medical options and improve people’s health outcomes. And participants like you are the key to completing research. Therefore, we hope that everyone within our community will continue to learn about, enroll in, and share research opportunities.
Read our additional blogs on HBOC research. FORCE belongs to the Metastatic Breast Cancer Alliance, a consortium of organizations working together to transform and improve the lives of women and men living with metastatic breast cancer. The Metastatic Breast Cancer Network, Living Beyond Breast Cancer, and Metavivor have specific resources for people with living with metastatic breast cancer.
Dr. Heather Han is a breast medical oncologist at Moffitt Cancer Center in Tampa, FL. Dr. Han researches outcomes among patients of different nationalities to determine affects of race on disparities in chemotherapy toxicity. She is principal investigator for studies using targeted breast cancer therapies designed to improve prognosis, reduce side-effects and improve quality-of-life.Tags: brca, BRCA 1, BRCA 2, brca research, BRCA1, BRCA2, breast cancer, clinical trials, gene testing, HBOC, hereditary cancer research, PARP inhibitor, personalized medicine, targeted therapy for cancer